Skip to content
MedsAcross

Medicine

Cipro HC 2 mg/10 mg per mL otic suspension

Available on requestPrescription onlyUS FDA

Cipro HC 2 mg/10 mg per mL otic suspension is a prescription medicine containing Ciprofloxacin and Hydrocortisone for otic use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Avoid freezing. Store at 20°C to 25°C (68°F to 77°F), excursions permitted…

Key facts

Active ingredient (INN)
Ciprofloxacin and Hydrocortisone
Brand
Cipro HC
Strength
2 mg/10 mg per mL
Dosage form
Otic suspension
Route
Otic
Packs
1 bottle, 10 mL and 1 more
Marketing authorisation holder
Sandoz
Manufacturers
SandozA-S Medication SolutionsAsclemed
Origin register
US FDA, United States
Storage
Avoid freezing. Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
15 March 1999
Identifiers
RxCUI 213320, 309305DailyMed set ID b26594a3-2adf-4954-8be0-5bd6f8de9671, eafad445-2735-434b-a1c6-e1c6b201d2cf, ab640d62-f470-4b50-818f-0c0a33904743 +1NDC 66758-087, 76420-273, 50090-6043 +1Application NDA020805

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle in 1 carton / 10 mL in 1 bottle66758-087-70Sandoz8 November 2024
10 mL in 1 bottle50090-6043-0A-S Medication Solutions15 July 2022
1 bottle in 1 carton / 10 mL in 1 bottle50090-7631-0A-S Medication Solutions14 August 2025
10 mL in 1 bottle76420-273-10Asclemed7 September 2022

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 10 February 1998Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Ciprofloxacin and Hydrocortisone 2 mg/10 mg per mL otic suspension.

Compare 1

Clinical summary

Ciprofloxacin and Hydrocortisone is a fixed-dose combination of a corticosteroid, a fluoroquinolone antibacterial and a quinolone antimicrobial indicated for the treatment of acute otitis externa in adult and pediatric patients, among other approved uses. MedsAcross supplies Ciprofloxacin and Hydrocortisone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Ciprofloxacin and Hydrocortisone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Cipro HC 2 mg/10 mg per mL otic suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.